文献类型：期刊文献

英文题名：Circulating cfdna: A novel biomarker for preventing early recurrence in ischemic stroke

作者：Li, Xinglan[1];Yuan, Yongjin[2];Jing, Weiyao[1];Liu, Cui[1];Wei, Mai[1];Liu, Qianru[1];Li, Xing[1];Wei, Long[1];Du, Xiaozheng[1];Wang, Jinhai[3]

第一作者：李旭立;李向丽;李小林

通信作者：Du, XZ[1];Wang, JH[2]

机构：[1]Gansu Univ Chinese Med, Dept Acupuncture Moxibust & Tuina, Lanzhou 730000, Peoples R China;[2]Lanzhou Hosp Tradit Chinese Med, Lanzhou 730000, Peoples R China;[3]Lanzhou Univ, Hosp 2, Dept Tradit Chinese Med, Lanzhou 730000, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Dept Acupuncture Moxibust & Tuina, Lanzhou 730000, Peoples R China;[2]corresponding author), Lanzhou Univ, Hosp 2, Dept Tradit Chinese Med, Lanzhou 730000, Peoples R China.|[10735]甘肃中医药大学;

年份：2025

外文期刊名：JOURNAL OF THROMBOSIS AND THROMBOLYSIS

收录：;Scopus(收录号：2-s2.0-105016599734);WOS:【SCI-EXPANDED(收录号:WOS:001571974100001)】；

基金：This study was supported by the National Natural Science Foundation of China (NSFC) (Project No.82460965 and NSFC Project No.82260962).

语种：英文

外文关键词：Ischemic stroke; NETosis; CfDNA; NET-DNA; AIM2; MMPs; DNase

摘要：Stroke is the second-leading cause of mortality and the principal contributor to long-term disability worldwide. Despite the widespread clinical implementation of secondary prevention protocols, the 90-day stroke recurrence rate remains a significant concern, particularly among patients with atherosclerosis. Mounting evidence implicates inflammatory pathways as central mediators in both atherogenesis and plaque destabilization. It is known that ischemic stroke triggers a substantial release of cell-free DNA (cfDNA) into the systemic circulation. These nucleic acid fragments can subsequently activate endothelial cells, thereby promoting atherosclerosis, and can also activate nucleotide-sensing inflammasomes within vulnerable plaques, thus triggering thrombotic cascades and early recurrent cerebrovascular events. In this review, we comprehensively examine the pathophysiological origins of cfDNA, delineate its mechanistic involvement in stroke recidivism, and evaluate current therapeutic strategies targeting cfDNA catabolism in the management of ischemic stroke, aiming to provide insights for future research in this field.